newsfilter
← Latest News
Business Wire·

Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results

ZTALMY® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million Over 75% of patients required for the interim analysis are now enrolled